What Are Guanylate Cyclase-C Agonists and How They Work?

Guanylate cyclase-C agonists are a class of drugs that treat constipation-predominant irritable bowel syndrome (IBS-C) and chronic idiopathic constipation by activating a receptor found on the inner lining of the intestine. The two approved members of this class, linaclotide and plecanatide, work by mimicking hormones that your gut already produces to regulate fluid balance. But the receptor they target, known as GC-C, turns out to do far more than move water into the intestinal lumen, and the science around it has expanded into pain signaling, colorectal cancer, blood pressure regulation, and even appetite control.

How GC-C Agonists Work Inside the Gut

Your intestinal lining is studded with GC-C receptors. Under normal circumstances, two small peptide hormones your body makes, guanylin and uroguanylin, bind to these receptors and trigger production of a signaling molecule called cyclic GMP (cGMP). That burst of cGMP sets off a chain of events that culminates in chloride and water being pushed into the intestinal space, keeping stool soft and transit moving. Linaclotide and plecanatide are synthetic peptides designed to do the same thing, just more reliably and at a controlled dose.

The downstream mechanics are worth understanding at a basic level because they explain why GC-C agonists differ from ordinary laxatives. When cGMP accumulates inside an intestinal cell, it activates an enzyme that in turn drives a chloride channel called CFTR to the cell’s surface. CFTR is the same channel that malfunctions in cystic fibrosis, so GC-C agonists are essentially commandeering an existing fluid-transport system rather than irritating the bowel wall the way stimulant laxatives do.¹ The result is a gentler, more physiological increase in intestinal fluid.

Pain Relief Through an Unexpected Route

For years, physicians assumed GC-C agonists helped IBS-C patients feel better simply because they relieved constipation. Fewer backed-up stools, less bloating, less pain. That explanation turned out to be incomplete. Research has shown that the cGMP generated inside intestinal cells does not all stay inside the cell. Some of it gets pumped out through the base of the cell, where it reaches nerve endings embedded in the gut wall.

When researchers applied linaclotide to intestinal tissue in the lab, they found that this extracellular cGMP directly quieted pain-sensing nerve fibers, reducing their response to mechanical stretching. Blocking the transporter that moves cGMP out of the cell eliminated the painkilling effect. Removing the mucosal lining altogether, which gets rid of the GC-C receptor source, also abolished it. And when they applied cGMP directly to nerve fibers in tissue where the lining had been stripped away, the pain-dampening effect returned in a dose-dependent fashion.² The effect was even more pronounced in tissue from mice with chronic visceral hypersensitivity, the animal model closest to IBS.

This matters clinically because it means GC-C agonists address two separate problems in IBS-C: slow transit and heightened visceral pain. Stimulant laxatives can speed things up but may actually worsen abdominal symptoms.³ Having a drug that handles both complaints through the same receptor system is a meaningful advantage.

Linaclotide Versus Plecanatide

Both approved GC-C agonists are small peptides taken by mouth that act locally in the gut and are barely absorbed into the bloodstream. Their differences are mostly in chemistry and where along the intestine they are most active.

Linaclotide is a 14-amino-acid peptide held together by three internal disulfide bonds, giving it a rigid shape that resists stomach acid well. It binds GC-C with high affinity regardless of the local pH, so it works throughout the small and large intestine.⁴ In the intestine, its half-life is under an hour before enzymes chop it up, but by then its job is done.

Plecanatide is modeled on the body’s own uroguanylin and has only two disulfide bonds. It is pH-sensitive, becoming most active in the mildly acidic environment of the duodenum (the first stretch of small intestine, where pH hovers around 5 to 6). It degrades rapidly once it hits the more alkaline lower intestine, with an intestinal half-life of about five minutes. To compensate for that fast breakdown, plecanatide is dosed roughly 10 to 40 times higher than linaclotide.⁵

In practice, both drugs produce similar clinical results. A systematic review and meta-analysis pooling data from multiple randomized trials found both linaclotide and plecanatide to be effective for chronic idiopathic constipation and IBS-C, though the odds ratios for linaclotide were somewhat higher at its approved doses.⁶ Whether that translates to a noticeable difference for a given patient is hard to say; many gastroenterologists will try one and switch to the other if the first doesn’t suit.

Side Effects and Who Should Not Take Them

The most common complaint with GC-C agonists is diarrhea, which is essentially an overshoot of the intended mechanism. Both linaclotide and plecanatide predominantly cause gastrointestinal adverse events, including diarrhea, abdominal pain, and bloating.⁷ The diarrhea is usually mild and dose-related, and it tends to decrease after the first week or two. Still, it is the leading reason people discontinue treatment.

Both drugs carry a black-box warning against use in children under 6 years old. In neonatal mice, GC-C agonists caused severe dehydration and death, because very young intestines have a higher density of GC-C receptors and are more sensitive to fluid shifts. The FDA extended caution to children aged 6 to 17 as well, though a phase 3 trial tested linaclotide in pediatric patients with functional constipation aged 6 to 17 and found it generally tolerable. One serious adverse event occurred: a 17-year-old developed severe diarrhea leading to dehydration and hospitalization, but recovered fully after intravenous fluids.⁸ Because the drugs act locally and are barely absorbed, systemic side effects are uncommon in adults.

How Bacteria Figured Out This Receptor First

Millions of years before pharmaceutical companies synthesized linaclotide, certain strains of E. coli had already evolved a molecule that activates GC-C. Enterotoxigenic E. coli (ETEC) produces a heat-stable enterotoxin, commonly called ST, that binds GC-C on intestinal cells and triggers a massive, uncontrolled secretion of chloride, sodium, and water into the gut lumen.⁹ The result is the profuse watery diarrhea that defines traveler’s diarrhea and is a major cause of childhood mortality in developing countries.¹⁰

The irony is striking: the same receptor hijacked by a toxin to cause diarrhea is the one targeted by prescription drugs to relieve constipation. The difference is dosing and context. Linaclotide at therapeutic concentrations produces a modest increase in luminal fluid. Bacterial ST floods the receptor with a massive, unregulated signal. Researchers recognized this connection early on and actually used ST peptides as research tools to map the GC-C signaling pathway long before anyone considered turning a controlled version into a drug.¹¹

GC-C and Colorectal Cancer Prevention

One of the more surprising findings in GC-C research is its apparent role as a tumor suppressor in the colon. Under normal conditions, the cGMP produced by GC-C activation helps regulate how fast intestinal cells divide, how readily they migrate, and when they undergo programmed cell death. When GC-C signaling is lost, those checks loosen.

The natural ligands for GC-C, guanylin and uroguanylin, disappear early in the process of colorectal tumor formation. In mice engineered to lack GC-C entirely, intestinal tissue shows features that look like early cancer: increased cell proliferation, accumulation of DNA mutations, and metabolic changes that favor tumor growth.¹² Conversely, when GC-C is activated by its natural ligands or by synthetic agonists, it suppresses several well-known cancer-promoting pathways and boosts tumor-suppressor proteins. Lab studies showed that GC-C agonists inhibited the proliferation of human colon cancer cell lines in a dose-dependent manner by slowing progression through the cell cycle.¹³

This has led some researchers to propose what they call the “paracrine hormone hypothesis”: colorectal cancer may not always begin as an irreversible genetic event but could sometimes arise from a reversible loss of the hormones that keep GC-C active. If that model holds, restoring GC-C signaling with an agonist could theoretically help prevent colon tumors in at-risk populations. No clinical trials in humans have tested this yet, and the leap from mice to cancer-prevention therapy in people is enormous, but the biological logic is provocative.

In a related line of work, the same ligand loss seen in tumors has been observed in ulcerative colitis, a chronic inflammatory bowel condition that raises colorectal cancer risk. Patients with active ulcerative colitis show significantly reduced levels of GC-C, guanylin, and uroguanylin, and the drop is proportional to disease severity.¹⁴ Animal studies have shown that GC-C agonists like plecanatide can reduce colitis severity in mice to a degree comparable to established anti-inflammatory drugs.¹⁵

GC-C as a Target for Cancer Immunotherapy

Beyond prevention, GC-C has attracted attention as a bulls-eye for cancer-killing therapies. Because GC-C is expressed at high and consistent levels on colorectal cancer cells but is confined almost exclusively to the intestinal lining in healthy tissue, it offers a relatively specific address for immune-based treatments to home in on.

A recent nonrandomized clinical trial tested a CAR T-cell therapy (called GCC19CART) engineered to recognize GC-C on metastatic colorectal cancer cells. Among 15 heavily pretreated patients, the objective response rate was 40%, and median overall survival reached about 23 months. Side effects included cytokine release syndrome and diarrhea, but all were manageable and self-limited.¹⁶ The investigators described it as the first CAR T-cell therapy to produce objective clinical activity in a refractory solid tumor of this type, which is a genuinely notable milestone given how difficult colorectal cancer has been to treat with immunotherapy. A subsequent phase I study further evaluated GC-C-targeted CAR T cells, confirming the receptor’s consistent expression across all stages of the disease.¹⁷

GC-C has also proved useful as a diagnostic marker. Because the receptor is expressed on colon tissue but not in lymph nodes, detecting GC-C messenger RNA in a lymph node is strong evidence that colon cancer cells have migrated there. In one study, this approach identified hidden metastases in lymph nodes of patients who had been staged as cancer-free by standard methods, upgrading their staging and potentially changing their treatment plan.¹⁸

A Gut-Brain Connection Through GC-C

The story of GC-C gets stranger when you look outside the intestine. Uroguanylin, the natural GC-C ligand released after eating, appears to function as a satiety hormone. Research has shown that eating triggers uroguanylin secretion from the small intestine, and this hormone travels through the bloodstream to activate GC-C receptors in the hypothalamus, the brain region that governs appetite and energy balance.¹⁹

In diet-induced obese mice, oral treatment with linaclotide caused significant weight loss without changing how much the animals ate. The mechanism appeared to involve GC-C receptors in the hypothalamus activating the sympathetic nervous system, which in turn switched on brown fat thermogenesis, essentially cranking up the body’s calorie-burning furnace.²⁰ Whether this translates to meaningful weight effects in humans taking linaclotide for constipation is unknown. The drug is taken at doses chosen for gut effects, and the fraction reaching the brain is tiny. But the finding opens a window into why GC-C ligand loss, which happens in obesity, might contribute to a self-reinforcing cycle of weight gain and metabolic dysfunction.

Blood Pressure and the Intestinal-Renal Axis

Uroguanylin has yet another job that has nothing to do with the gut per se. After you eat a salty meal, uroguanylin released from the intestine travels to the kidneys and promotes sodium excretion. Mice engineered to lack uroguanylin develop elevated blood pressure and cannot properly dump excess sodium into their urine after an oral salt load, largely because their kidneys inappropriately reabsorb too much sodium.²¹²²

This represents an intestinal-renal endocrine axis: the gut senses incoming salt, releases uroguanylin, and the kidneys respond by flushing the excess out. When this axis malfunctions, the body retains sodium, blood volume rises, and blood pressure goes up. Follow-up work found that uroguanylin cooperates with dopamine receptors in the kidney to promote sodium excretion, and that disrupted interaction between these two systems may contribute to hypertension.²³ None of this has yet led to a blood-pressure drug, but it suggests that GC-C agonist biology touches the cardiovascular system in ways that are only beginning to be mapped.

Next-Generation Drug Design

One limitation of current GC-C agonists is that they are peptides, and peptides get chewed up by digestive enzymes. Linaclotide survives the stomach well but has an intestinal half-life of under an hour. Plecanatide degrades in minutes once it leaves the duodenum. Pharmaceutical chemists are working on modified versions with better stability.

One group systematically altered linaclotide’s structure and produced analogues with intestinal half-lives exceeding eight hours, compared to about 48 minutes for unmodified linaclotide.²⁴ Longer-lasting peptides could allow lower doses, potentially reducing diarrhea rates, or could extend the drug’s action into the lower colon, which might matter for conditions like distal colitis or left-sided colorectal cancer prevention.

Another experimental compound, dolcanatide, was designed to resist both gastric and intestinal breakdown. In mouse models of colitis, it performed comparably to established anti-inflammatory drugs, suggesting it might eventually bridge the gap between constipation treatment and inflammatory bowel disease therapy.²⁵ Whether any of these next-generation peptides will reach patients depends on clinical trials still years away, but the chemistry is progressing steadily.